Targets: Doravirine is a just lately licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and security profile in contrast with efavirenz and restricted cross-resistance with rilpivirine and
![Expression Pathology Inc. (EPI) Biotechnology](https://www.expressionpathology.com/js/uploads/2021/04/express.jpg)
Expression Pathology Inc. (EPI) Biotechnology
Multiplex tissue proteomic assays using FFPE IHC analysis